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Late-onset familial Alzheimer disease (LOFAD) is a genetically heterogeneous and complex disease for which only
one locus, APOE, has been deﬁnitively identiﬁed. Difﬁculties in identifying additional loci are likely to stem from
inadequate linkage analysis methods. Nonparametric methods suffer from low power because of limited use of the
data, and traditional parametric methods suffer from limitations in the complexity of the genetic model that can
be feasibly used in analysis. Alternative methods that have recently been developed include Bayesian Markov chain–
Monte Carlo methods. These methods allow multipoint linkage analysis under oligogenic trait models in pedigrees
of arbitrary size; at the same time, they allow for inclusion of covariates in the analysis. We applied this approach
to an analysis of LOFAD on ﬁve chromosomes with previous reports of linkage. We identiﬁed strong evidence of
a second LOFAD gene on chromosome 19p13.2, which is distinct from APOE on 19q. We also obtained weak
evidence of linkage to chromosome 10 at the same location as a previous report of linkage but found no evidence
for linkage of LOFAD age-at-onset loci to chromosomes 9, 12, or 21.
Introduction
Alzheimer disease (AD) is genetically heterogeneous.
Rare autosomal dominant mutations in the amyloid pre-
cursor protein (APP [MIM 104760]) (Goate et al. 1991),
presenilin 1 (PSEN1 [MIM 104311]) (Schellenberg et al.
1992; Sherrington et al. 1995), and presenilin 2 (PSEN2
[MIM 600759]) (Levy-Lahad et al. 1995a, 1995b; Ro-
gaev et al. 1995) cause early-onset familial AD (FAD),
but late-onset FAD (LOFAD) is more complex. Apoli-
poprotein E (APOE [MIM 107741]) is the single deﬁn-
itive LOFAD gene, identiﬁed primarily with population-
based studies (Corder et al. 1993), but the high-risk 4
allele is neither necessary nor sufﬁcient to cause disease
(Corder et al. 1993; Strittmatter et al. 1993). Different
studies also estimate that APOE accounts for only 4%–
15% of the variance in age at onset (Bennett et al. 1995;
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Slooter et al. 1998; Daw et al. 2000b; Tunstall et al.
2000). Recent oligogenic segregation analysis of FAD
age at onset as a quantitative trait suggests that there
are several contributing genes that have not yet been
identiﬁed (Daw et al. 2000b). Consistent with this ﬁnd-
ing, linkage analysis of families with LOFAD has pro-
duced multiple candidate regions with some support in
more than one data set (Pericak-Vance et al. 1997; Kehoe
et al. 1999; Curtis et al. 2001; Olson et al. 2001;Mayeux
et al. 2002; Blacker et al. 2003; Scott et al. 2003). In
addition to modest evidence of linkage to the APOE
region on chromosome 19 (Pericak-Vance et al. 1991,
2000; Kehoe et al. 1999; Blacker et al. 2003), the most
consistent evidence for linkage of AD loci has been re-
ported for chromosomes 10 (Bertram et al. 2000; Er-
tekin-Taner et al. 2000; Myers et al. 2000) and 12
(Blacker et al. 1998; Scott et al. 1999; Mayeux et al.
2002). Somewhat weaker evidence for linkage to chro-
mosome 9 has been reported across samples (Kehoe et
al. 1999; Pericak-Vance et al. 2000; Myers et al. 2002),
and reports of linkage of LOFAD to the APP region in
the National Institute of Mental Health (NIMH) AD
sample (Kehoe et al. 1999; Curtis et al. 2001; Olson et
al. 2001; Bacanu et al. 2002; Myers et al. 2002) are of
interest because of the known role of APP in early-onset
AD. Interpretation of these results and expectation for
future success in gene mapping is tempered by the dif-
ﬁculty of identifying APOE with traditional mapping
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methods; in addition, positive reports of linkage to other
chromosomes vary considerably in location among stud-
ies, raising questions about the strength of the evidence.
As for all complex traits, replication in independent data
sets remains a key aspect of validation of a positive link-
age report.
Localization of susceptibility genes for complex dis-
orders such as AD is difﬁcult because of heterogeneity,
unknown modes of inheritance, and the potentially small
effects exerted by any single gene. AD gene detectionwith
model-free approaches is hampered by the intrinsic low
power of these methods (Durner et al. 1999). Traditional
single-locus model-based approaches lose power because
of poor speciﬁcation of single-locus model parameters
and because of restrictions in the number of trait loci
that can be explicitly incorporated into the analysis. Het-
erogeneity LOD score methods (Smith 1961; Hodge et
al. 1983) fail to adequately incorporate the complexity
of a trait affected by more than simple genetic hetero-
geneity. Computationally demanding two-trait-locus
methods have occasionally been attempted (Schork et al.
1993; Tienari et al. 1994; Goldstein et al. 1996) but have
limited practical utility, even with current fast computers.
The extension of model-based methods to more trait loci,
particularly in the context of multipoint marker analy-
sis, remains computationally infeasible (Wijsman 2003).
However, because results both from genome screens (Per-
icak-Vance et al. 1997; Blacker et al. 1998; Kehoe et al.
1999; Scott et al. 1999, 2003; Bertram et al. 2000; Er-
tekin-Taner et al. 2000; Myers et al. 2000, 2002) and
from oligogenic segregation analysis (Daw et al. 2000b)
suggest that several loci are involved in LOFAD, it is
reasonable to expect that models that incorporate more
of this trait-locus complexity might improve the power
and accuracy of AD gene localization (Wijsman and
Amos 1997; Daw et al. 1999).
Bayesian Markov chain–Monte Carlo (MCMC) link-
age analysis methods provide a computationally trac-
table approach for complex-trait analysis. These meth-
ods are particularly suitable for multilocus trait models
and easily accommodate the substantial missing geno-
type data that is typical of AD data sets. These methods
use the available data more efﬁciently than either trait-
model–free analysis or parametric analysis using an in-
adequate single-locus model. Current implementations
of QTL methods (Heath 1997) have been extended to
censored data (Daw et al. 1999), allowing application
to the mapping of FAD age-at-onset QTLs. These meth-
ods make efﬁcient use of available data, because mul-
tipoint analysis with many markers is possible with ped-
igrees of any size and with any amount of missing data
and because the analysis can include covariates (Wijs-
man and Amos 1997). The MCMC multipoint com-
putations are accurate and produce results that are
superior to approximation-based methods (Wijsman
2003), resulting in increased power to detect linkage
(Go¨ring et al. 2003). Bayesian MCMC linkage analysis
methods have performed well with both real (Daw et
al. 1999; Yuan et al. 2000; Gagnon et al. 2003; Chap-
man et al., in press) and simulated (Heath et al. 1997;
Shmulewitz and Heath 2001) data. These methods do
not require knowledge of a prespeciﬁed trait-locus
model, since estimation of the model is part of the anal-
ysis. Alternative approaches, such as variance-compo-
nents methods (Amos 1994; Almasy and Blangero
1998), lead to computational difﬁculties resulting from
the extensive missing genotype data that is typical of
AD; these methods also can suffer from loss of power
(Forrest and Feingold 2000) or false-positive evidence
of linkage (Williams et al. 1997) because of the violation
of distributional assumptions when pedigrees are not
randomly ascertained, as is typical of pedigrees with
AD.
Here we present results of an MCMC analysis of ped-
igrees with LOFAD for ﬁve chromosomes with evidence
of linkage from previous studies. Chromosomes 9, 10,
12, 19, and 21 were chosen for investigation because of
prior positive reports of linkage to AD in more than one
data set. With the exception of chromosome 21, the pre-
vious positive linkage results all included more than one
sample of pedigrees with LOFAD. For chromosome 21,
the known role of APP in early-onset AD complements
the evidence for linkage in the late-onset NIMHAD data
set. Our analyses provide evidence for linkage to APOE,
implicate a novel AD age-at-onset gene on chromosome
19p13.2, and provide support for an AD gene on chro-
mosome 10 near a location previously implicated on this
chromosome. In contrast to the results for chromosomes
19 and 10, there was little evidence in our data set for
linkage of age at onset of LOFAD to chromosomes 9,
12, or 21 in regions with previously reported evidence
for linkage.
Methods
Families with LOFAD
A total of 86 multiplex kindreds with LOFAD were
used. Families were identiﬁed and characterized primarily
by the University ofWashington AD genetics group. Fam-
ilies were also identiﬁed at the Oregon Health Sciences
University and the University ofMinnesota. Samples from
an additional eight families were from the National Cell
Repository for Alzheimer’s Disease. The study was ap-
proved by the University of Washington institutional re-
view board. Families were considered to have LOFAD if
the family mean age at onset was 60 years. Families
were not included in the analysis if they contained subjects
with identiﬁed mutations in APP, PSEN1, PSEN2, mi-
crotubule-associated protein tau (MAPT [MIM157140]),
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or prion-related protein (PRP [MIM 176640]). Families
consisted of 940 individuals (range 4–53 subjects per fam-
ily; median 9; mean 10.9; SD 7.3), including 340 affect-
ed subjects with known age at onset and 419 unaffected
individuals with known censoring age. DNA was ob-
tained from 527 of these subjects, including 274 affected
subjects (10 of whom were missing age-at-onset infor-
mation) and 253 unaffected individuals (9 of whomwere
missing censoring age information). The average number
of affected subjects per family in the portions of the
families used in the linkage analysis was 4.5 (range 2–
12), and the average number of subjects with AD sam-
pled per family was 3.3 (range 1–7). The observed mean
age at onset for the complete sample used in the analysis
was 70.7 years (range 40–89 years).
A clinical diagnosis of AD for living subjects was
based on published criteria (McKhann et al. 1984). For
deceased subjects, if no autopsy was available, the di-
agnosis of probable AD was based on detailed medical
records that included consultations by neurologists, neu-
ropsychological testing, magnetic resonance imaging of
the brain, and laboratory tests to exclude other forms
of dementia. Autopsies were obtained for 147 subjects,
with 74 families having at least one autopsied subject.
Autopsy criteria for AD were from the Consortium to
Establish a Registry for Alzheimer’s Disease (Mirra et
al. 1991) and the Ronald and Nancy Reagan Research
Institute of the Alzheimer’s Association/National Insti-
tute on Aging Working Group (1998). The ages at onset
of affected individuals were determined as described else-
where (Bird et al. 1989), and censoring age of unaffected
individuals (if cognitively intact) was based on age at
death or most recent age for which there was evidence
of normal cognitive function.
Genotyping Methods
Genotypes were determined by use of ﬂuorescence-
tagged primers to PCR-amplify STRPs. Fragments were
resolved by use of Perkin Elmer Biosystems 377 or 310
instruments and analyzed by use of GeneScan and Ge-
notyper software. APOE genotypes were obtained as
described elsewhere (Hixson and Vernier 1990; Levy-
Lahad et al. 1995b).
Marker Panels and Maps
Chromosome scans were based on markers spaced at
∼10-cM intervals for each chromosome (scanning
marker sets), by use of the ABI Prism 10-cM marker set
(version 2.5). Nine additional markers were subse-
quently added in the region on chromosome 19p for
which evidence for linkage was obtained, providing a 2-
to 3-cM spacing in the 19p region with evidence for
linkage (complete set of chromosome 19 markers).
Marker maps used for analysis were taken from the
Marshﬁeld Center for Medical Genetics Web site and
converted to a Haldane map for analysis. A sex-averaged
map was used for most analyses, and all genetic distances
and locations given here correspond to the Haldane
map. Because of concerns that a positive linkage signal
could be erroneous under the use of sex-averaged maps
(Daw et al. 2000a), a few analyses also were repeated
with sex-speciﬁc maps. However, because results were
unaffected by the use of sex-speciﬁc maps, they are not
presented. For all analyses, marker allele frequencies
were estimated from the families, which tends to give
conservative results (Ott 1992).
Candidate-Gene Covariate Loci
Because of previous results, three loci were included
as major-gene covariates in some analyses. The use of
such loci as candidate-gene covariates is important for
two reasons. First, if inclusion of a gene as a covariate
eliminates a linkage signal, this provides evidence sup-
porting a contribution of the locus to the trait. Second,
adjustment for the effects of covariates reduces the re-
sidual variance. This, in turn, increases the proportion
of the remaining variance explained by any given QTL,
which increases the power to detect such QTLs. APOE
was included as a candidate-gene covariate in most anal-
yses because of the strong and consistent evidence that
it is involved in LOFAD. The only exception to the in-
clusion of APOE as a major-gene covariate was in initial
analyses of chromosome 19, which were based only on
the scanning marker set as a test to see if the MCMC
methods could detect evidence for linkage to APOE
with a standard 10-cM panel of markers. On chromo-
some 12, two linked candidate loci were investigated:
a-2-macroglobulin (A2M [MIM 103950]) and low-den-
sity lipoprotein receptor-related protein (LRP [MIM
107770]). These were investigated as genes potentially
responsible for the chromosome 12 LOFAD locus for
three reasons: (1) previous linkage analysis reports by
other researchers (Blacker et al. 1998; Scott et al. 1999;
Mayeux et al. 2002); (2) the genes are APOE receptors
with some evidence for association with AD (Lendon et
al. 1997; Wavrant-DeVrie`ze et al. 1997; Blacker et al.
1998); and (3) corroboratory experimental evidence in
mice (Zerbinatti et al. 2004). We examined the age-at-
onset distributions for different genotypes for these two
loci so that we could address two questions. First, we
could determine whether age-at-onset distributions dif-
fer among genotypes. Second, we could determine the
form of the distributions: unimodal distributions with
genotype-speciﬁc means are all consistent with a model
of a shift in age at onset (Breitner et al. 1998), whereas
bimodal distributions are consistent with a shift in ge-
notype-speciﬁc risk without, necessarily, a shift in age at
onset within modes. In our analysis, these two loci were
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analyzed jointly as two independent major-gene covar-
iate loci.
Statistical Analysis
Age at onset was modeled as a censored quantitative
trait in a Bayesian MCMC joint linkage and oligogenic
segregation analysis. Age at onset was used as the phe-
notype for four reasons. First, it is a measure of severity
that is also a surrogate for AD. Second, there is evidence
for a genetic basis for age at onset (Meyer and Breitner
1998; Daw et al. 2000b; Pedersen et al. 2001). Third,
the use of continuous traits can be advantageous in link-
age analysis (Wijsman and Amos 1997). Finally, the
method of analysis used, which allows for an oligogenic
mode of inheritance, has been implemented only for con-
tinuous traits. The theory and methods are described
more extensively elsewhere (Heath 1997; Daw et al.
1999; Wijsman 2002; Wijsman and Yu, in press). The
program Loki, version 2.4.5, was used for analysis. The
analysis model included an unknown but estimated
number of underlying diallelic QTLs that contribute ad-
ditively to age at onset. Each locus is modeled as a dial-
lelic locus, according to standard QTL methods, with
genotype effects for QTL i parameterized asai and di
for the two homozygous and the heterozygous geno-
types, respectively (Falconer 1995). The overall model
is a standard linear model that combines QTL effects,
covariate effects, and environmental effects, with no in-
teractions, as described elsewhere (Heath 1997). The
analysis was a survival analysis, under the assumption
that within each multilocus genotype, deﬁned by all
QTLs in the model plus the covariate candidate-gene
genotypes (when included), the failure curves are cu-
mulative normal distributions with equal variance (Daw
et al. 1999). A sex-averaged meiotic map was used for
most analyses, under the assumption of a complete ge-
nome length of 3,000 cM. Results were unaffected by
the use of sex-speciﬁc maps and are not shown. Sensi-
tivity of results to errors in map distances was evaluated
by performing analyses for individual markers in the 20-
to 40-cM interval containing the strong signal on chro-
mosome 19p, since such single-marker analyses do not
incorporate assumptions about the genetic map. All link-
age analyses were based on 500,000 MCMC iterations,
with every 5th iteration used for computation of pos-
terior distributions. This run length was chosen on the
basis of extensive prior experience showing that long
runs are needed for analysis of censored traits and that
runs of this length give highly reproducible results.
The Bayesian aspect of the analysis combines prior
distributions with Metropolis-Hastings steps (Metro-
polis et al. 1953; Hastings 1970). The prior distributions
are used to propose new values for parameters in the
model. The Metropolis-Hastings steps compare the
probability of the observed data under the proposed and
current set of model parameters and use the ratio of the
two probabilities to determine whether or not to accept
the changes in the parameter values. Over many itera-
tions, the parameter values accepted can be regarded as
being drawn from the marginal posterior parameter dis-
tribution, which, in turn, can be used to draw inferences
about parameters of interest (Tierney 1994). For our
analyses, we used default values for the prior distribution
on QTL locations (uniform over the genome) and for
QTL allele frequencies (uniform on 0–1). The prior dis-
tribution on the number of QTLs was assumed to be
Poisson with mean 2. The ﬁnal prior distribution was
that of the QTL genotype effects and , which werea di i
sampled from a normal distribution with mean 0 and
variance . The value used for was 100, except wheret tb b
noted; early analyses in the absence of markers showed
that, when , the acceptance of models with newt p 100b
QTLs in the oligogenic trait model was maximized, and
thus a value of 100 was reasonable to use in analysis
(Wijsman and Yu, in press). A few additional analyses
were done with different values for , to explore thetb
sensitivity of results to assumptions about this parameter
value. Most runs were performed only once, but a set
of runs performed to evaluate the strength of the linkage
signal, described below, provides information pertaining
to interrun variability, which was low.
Because this is a Bayesian approach and does not pro-
duce conventional LOD scores or P values, twomeasures
of the strength of the signal were used to evaluate the
linkage signals. The ﬁrst is the maximum intensity ratio
(IR) over all map intervals considered. The IR reﬂects
the ratio of observed to expected acceptance rates of
QTLs with a location in a particular interval, and, in
interval i, (Wijsman and Yu, in press).IR p N /Ni ir i0
Given the observed marker and trait data, is theNir
observed number of times in an analysis run that a model
contained a QTL with a location in interval toi d
, for small d. is the equivalent number expectedi d Ni0
under a uniform distribution over the genome of all of
the average number of QTLs in the model. For com-
puting IRs, we used cM (giving 2-cM bins). Thedp 1
IR based on the estimated number of QTLs is a con-
servative estimate of the Bayes factor (Wijsman and Yu,
in press), so that an IR 1150 can be interpreted as very
strong evidence against the null hypothesis of no linkage,
provides strong evidence, and20 ! IR ! 100 3 ! IR !
provides positive evidence against the null hypothesis20
(Kass and Raftery 1995). The IR is computed for small
chromosome intervals. Although in multipoint analysis
the linkage signal is typically concentrated in a small
region, in single-marker analysis the linkage signal is
necessarily more diffuse, resulting in lower IRs. Thus,
to compare single-marker and multipoint analyses, we
also computed the posterior probability of linkage (PPL)
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Figure 1 MCMC multipoint linkage analysis of chromosome
19, expressed as the IR, with a prior variance on QTL genotype effects
of . The solid line indicates results obtained with the 12mark-t p 100b
ers in the marker screening panel. The dashed line denotes results
obtained when APOE was added as a 13th marker. The heavy dotted
line shows results when APOE was added as both a 13th marker and
a covariate. The vertical light dotted line marks the location ofAPOE,
and the horizontal light dotted line represents . Marker loca-IRp 1
tions are indicated by tick marks on the top horizontal axis. Markers,
from left (19p) to right (19q), are D19S209, D19S216, D19S884,
D19S221, D19S226, D19S414, D19S220, D19S420, D19S902,
D19S571, D19S418, and D19S210.
to the chromosome, to capture the global support for
linkage provided by each analysis. The second measure
of the strength of evidence for linkage was obtained by
the maximum log of the PPL (LOP score) (Daw et al.
2003), which has an interpretation similar to that of a
LOD score when parameters of the linked trait locus are
estimated in the context of the linkage analysis. A LOP
score is a comparison of the observed signal to one ex-
pected in the absence of linkage, as estimated by sim-
ulation, and is expected to be 0 in the absence of linkage:
P (x d y )r ic rLOP p logic 10{ }P (x d y )s ic s
where i represents position on the chromosome, andyr
represent the realized and simulated marker data onys
the pedigree, and represents a location proposal ac-xic
cepted, during the MCMC process, in interval toi d
for location of a QTL with variance contributioni d
between and , for small values of d and .c  c 
We used cM and years. The probabilitydp 1 p 0.5
(P) is estimated from the real data ( ) and the simulatedPr
data ( ), respectively. The simulated marker data werePs
generated by gene dropping on pedigrees of identical
structure and identical missing data patterns as the real
pedigrees, by use of the same markers, maps, and allele
frequencies as were observed in the real data. The es-
timated marker map was used in conjunction with Hal-
dane’s mapping function to govern the multilocus mar-
ker inheritance patterns. Trait phenotypes were ignored
during this step, thus producing a realization of marker
genotypes that would be expected in the absence of link-
age. LOP scores were computed by use of all markers
on chromosome 19, as well as APOE, which was in-
cluded as both a marker and a major-gene covariate.
The ﬁnal LOP score was based on 5,000,000 total
MCMC iterations, accumulated across 10 runs, each of
which was based on the real data plus one simulated
chromosome 19. Details for estimating the LOP score
are described elsewhere (Daw et al. 2003). Analysis con-
ditions were identical to those used for the analysis of
the complete set of markers on chromosome 19, with
, except that every 2nd iteration was saved fort p 200b
analysis, providing 2,500,000 iterations from which the
LOP score was estimated.
Results
Chromosome 19
Since theMCMC analysis methods are relatively novel,
we ﬁrst attempted to detect linkage to APOE, the single
known LOFAD gene (ﬁg. 1). As in all the analyses pre-
sented here, age at onset was used as a quantitative trait
to identify AD susceptibility loci. When chromosome 19
markers from the 10-cM scanning marker set were ini-
tially used in an MCMC oligogenic multipoint linkage
analysis without including APOE as either a marker or
covariate, a weak signal (maximum , ∼80 cM)IRp 2.3
near APOE on 19q was observed but was shifted slightly
telomeric toAPOE.The signal nearAPOE increased con-
siderably in strength when APOE was included as a
marker, and the peak IR ( , ∼75 cM) providedIRp 9.97
positive evidence of linkage and was much closer to the
correct APOE location. Finally, the IR dropped again
when APOE was included both as a covariate and as a
marker ( , ∼83 cM). These results are all consis-IRp 2.7
tent with APOE as the cause of the 19q signal.
We also identiﬁed evidence for a second linkage peak
on 19p. In the initial analysis, which was based on the
10-cM scanning marker set, we observed a peak on 19p
at ∼30 cM on the Haldane map (ﬁg. 1). The magnitude
of this initial peak was small ( , ∼29 cM), butIRp 1.47
it rose slightly when APOE was included as a marker
but not as a covariate in the analysis ( , ∼31 cM).IRp 2
When APOE also was included as a covariate, the signal
at 19p increased considerably ( , ∼29 cM). ToIRp 10
further characterize the 19p signal, genotypes frommark-
ers selected at 2- to 3-cM intervals surrounding the 19p
peak were then included (ﬁgs. 2 and 3) to provide the
complete marker set—in all cases, with APOE used as
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Figure 2 MCMC multipoint linkage analysis, with 21 markers
plus APOE, which was used as both a marker and a major-gene co-
variate. The solid line indicates , and the dashed line repre-t p 100b
sents . The vertical light dotted line shows the location oft p 200b
APOE. APOE genotypes were inferred probabilistically for all indi-
viduals with missing genotypes, and age at onset was estimated for
all sixAPOE genotypes. Tick marks on the top horizontal axis indicate
marker locations, with long ticks corresponding to the same markers
as in ﬁgure 1 and short ticks corresponding to an additional nine
markers. From left to right, the markers are D19S209, D19S894,
D19S216, D19S869, D19S395, D19S884, D19S391, D19S916,
D19S394, D19S221, D19S914, D19S564, D19S226, D19S915,
D19S414, D19S220, D19S420, D19S902, D19S571, D19S418, and
D19S210. (Markers D19S221 and D19S914 are so close together that
the ticks are indistinguishable.)
Figure 3 Results from run with in ﬁgure 2, showingt p 100b
position and genetic effect of the 19p linkage signal relative to the
background signal. The vertical axis is proportional to the posterior
probability of a gene at a particular location (the intensity) and with
the indicated QTL size (square root of the genetic variance).
both a marker and a major-gene covariate. This strongly
increased the 19p signal ( , ∼35 cM). TheIRp 117.5
median location of all models accepted by the MCMC
analysis was 34.9 cM, with the lower and upper 25th
percentiles falling at 34.04 cM and 35.69 cM, respec-
tively, and the lower and upper 10th percentiles at 31.3
cM and 38.1 cM, respectively. The markers ﬂanking
these lower and upper 10th percentiles are D19S391
(30.64 cM) and D19S914 (38.22 cM).
The results were not strongly affected by assumptions
of the analysis. The sensitivity of the 19p signal to choice
of was evaluated. An increase of from 100 to 200t tb b
further increased the IR to 229 (ﬁg. 2). Increases of tb
to larger values, as well as decreases of to !100, re-tb
sulted in a decrease of the IR: for , the IR wast p 50b
61, whereas for , the IR was 170. This is con-t p 400b
sistent with the hypothesis that values of in the rangetb
of 100–200 provide models with the best ﬁt to the data.
Multiple runs, when performed, gave consistent results:
the 10 separate runs used to estimate the LOP score were
consistent with the initial run ( ), giving a meant p 100b
IR of 254, an SD of 23.2, and a coefﬁcient of variation
of 9%. Finally, the possibility of map error leading to
inﬂation of the linkage signal for these closely spaced
markers (Daw et al. 2000a) was explored by MCMC
analysis of individual markers; markers at 26–38 cM on
the map all gave maximum IRs 12, eliminating map
misspeciﬁcation as the sole source of the positive signal
(results not shown). The highest individual marker IRs
were at the ﬂanking markers D19S884 ( ) andIRp 10
D19S391 ( ). For these two analyses, the PPLsIRp 12.5
were 0.11 and 0.13, respectively. In comparison, for the
analysis based on all the markers, the PPL was 0.24.
Since the total number of QTL locations accepted on all
of chromosome 19 in the analysis with all the markers
was only 1.8 times the number accepted in the analysis
with D19S391, the lower maximum IRs for the single-
marker analyses are partly explained by the more diffuse
QTL localizations in these single-marker analyses. For
example, for D19S391, the upper and lower 25th and
10th percentiles of QTL locations spanned 21.3 cM and
50.62 cM, respectively, compared with only 1.65 cM
and 6.8 cM, respectively, for the analysis that included
all the markers. The presence of a linkage signal ob-
served individually with two ﬂanking markers, coupled
with the resulting large increase in the multipoint linkage
signal in the presence of adjustment for APOE genotype
effects—from an IR of ∼10 to one of ∼230—supports
the existence of a LOFAD age-at-onset QTL on 19p. In
addition, a maximum LOP score of 4.1 for an analysis
with the full set of markers provides strong evidence of
linkage of an age-at-onset QTL to 19p at 34–36 cM on
the Haldane map (ﬁg. 4). In contrast, for the same set
of runs, the maximum LOP score in the vicinity of
APOE was only 1.3 at ∼76 cM.
The size for this new QTL on 19p was substantial.
The mean size of 8.4 years  1.6 years for QTLs map-
ping to the interval between 30–38 cM was clearly
higher than that of the small QTLs along the chromo-
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Figure 4 LOP score distribution for chromosome 19 (t pb
; 2,500,000 scored iterations), showing position and genetic effect100
of the 19p linkage signal relative to the background signal. The vertical
axis is on a log10 scale.
some that are routinely included in the model (ﬁg. 3).
This size of the QTL at 19p, after adjustment for APOE
effects, appears to be somewhat larger than that esti-
mated for APOE (5.4 years  0.7 years in the current
analysis and 4.5 years in a previous analysis [Daw et al.
2000b]). The trait-model parameters for the 19p QTL
are also similar to those estimated in the absence of
markers (Daw et al. 2000b) for the largest QTL segre-
gating for age at onset: the gene frequency for the major
allele in the current analysis is 0.58 (0.07 SD), compared
with 0.6; the heterozygote effect relative to the common
homozygote effect in the present study was 9.3 years
(2.3 SD), compared with a previous effect of7.8 years;
and the rarer homozygote effect in the present study was
15.05 years (6.06 SD), compared with 28.8 years. As
reported by Daw et al. (2000b), the model estimated in
the current analysis is overdominant.
Chromosome 9
There was evidence against linkage of an age-of-onset
QTL on chromosome 9 to the region with previous re-
ports of linkage (ﬁg. 5A). The IRs were !1 in this region,
providing strong evidence against linkage. The maxi-
mum IR on the chromosome was ∼1.7 at ∼80 cM (ﬁg.
5A), obtained only with a low value of 25 for . Thetb
IR at this location decreased with higher values of .tb
With the exception of the IR 11 in the middle of the
map, IRs elsewhere on the chromosome were all !1, as
would be expected in the absence of linkage.
Chromosome 10
There was weak evidence supporting the existence of
a QTL near a previously reported region on chromo-
some 10 (ﬁg. 5B). The IR is !1 for most of the chro-
mosome, but it increases to ∼2 at the location of one of
the reports of a chromosome 10 AD locus (Ertekin-Taner
et al. 2000; Myers et al. 2000, 2002). This signal was
relatively insensitive to choice of , giving approxi-tb
mately the same results for and for .t p 25 t p 100b b
There was also a second, very weak signal near the lo-
cation of the second region reported on chromosome 10
at ∼145 cM, but this signal was sensitive to the value
for , decreasing for both increasing as well as decreas-tb
ing values of .tb
Chromosome 12
We obtained evidence against linkage of a QTL to the
chromosome 12 location with previous reports of link-
age (ﬁg. 5C). The IR was !1 for most of the chromo-
some, slightly exceeding 1 only near 100 cM, with a
peak IR of ∼1.5 for . The IR at the A2Mt p 25–100b
location was ∼0.7, providing no evidence for a contri-
bution of this locus to age at onset. In addition, we found
no evidence for genotype-speciﬁc effects on age at onset
for either LRP or A2M when these genes were addi-
tionally included as major-gene covariates. Both of these
genes were investigated as candidate loci because they
are APOE receptors and are located near regions with
previous reports of linkage, as well as because of pre-
vious reports of association with AD (Lendon et al.
1997; Wavrant-DeVrie`ze et al. 1997; Blacker et al.
1998). For LRP, the possible genotypes all had virtually
identical onset distributions, with shifts relative to the
most common homozygous genotype of 0.06 years
1.91 years and 0.88 years  4.46 years for the het-
erozygote and rarer homozygote, respectively. ForA2M,
there is weak evidence that the 2/2 genotype may have
a later onset than the 1/1 and 1/2 genotypes, with mean
onsets of 0.12 years  1.71 years and 4.44 years 
5.02 years for the 1/2 heterozygote and 2/2 homozygote,
relative to the 1/1 homozygote, respectively. However,
the direction of the effect and the apparent mode of
inheritance, if there is an effect, differ from the original
report of an A2M AD association (Blacker and Tanzi
1998). Also, the posterior distributions include 0 within
1 SE of the estimated effects, consistent with an inter-
pretation that the results are statistically insigniﬁcant.
Chromosome 21
For chromosome 21, the IR was !1 for the entire
chromosome (ﬁg. 5D). The IR near APP was ∼0.25,
providing strong evidence against linkage of an age-at-
onset QTL to this region. Varying the value for didtb
not change these results (not shown).
Additional QTLs
Although the purpose of the present analysis was an
investigation of linkage to several key chromosomes, the
results obtained provide information pertinent to future
linkage analyses. The 19p locus explains ∼52% of the
genetic variance in this sample, after adjustment for
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Figure 5 MCMC multipoint linkage analysis results for chromosomes 9, 10, 12, and 21. Tick marks on the top horizontal axis represent
marker locations. Chromosome 9 markers: D9S288, D9S286, D9S285, D9S157, D9S171, D9S161, D9S1817, D9S273, D9S175, D9S167,
D9S23, D9S287, D9S1690, D9S1677, D9S1776, D9S1682, D9S290, D9S164, D9S1826, D9S158. Markers on chromosome 10: D10S249,
D10S591, D10S189, D10S547, D10S1653, D10S548, D10S197, D10S208, D10S196, D10S1652, D10S537, D10S1686, D10S185, D10S192,
D10S597, D10S1693, D10S587, D10S217, D10S1651, and D10S212. Chromosome 12 markers: D12S352, D12S99, D12S336, D12S364,
D12S310, D12S1617, D12S1042, D12S345, D12S1090, D12S85, D12S368, D12S390, D12S83, D12S326, D12S351, D12S346, D12S78,
D12S79, D12S86, D12S324, D12S1659, and D12S1723. Chromosome 21 markers: D21S1911 (0 cM), D21S1904, D21S1899, D21S1884,
D21S1922, D21S214, D21S1914, D21S269, D21S263, D21S1252, D21S1255, and D21S266. Vertical lines indicate the locations of previously
reported linkage signals.
APOE effects, leaving ∼48% of the genetic variance un-
explained. The posterior distribution of the QTLs had
a mean of 3.54 (1.14 SD). Among the QTLs not ex-
plained by the 19p locus was one additional large un-
linked QTL with an essentially dominant mode of in-
heritance, a common allele frequency of 0.82 (0.07 SD),
a genotypic effect for the heterozygote relative to the
common homozygote of 2.3 years (5.45 SD), and a ge-
notypic effect for the rare homozygote relative to the
common homozygote of 19.71 years (4.63 SD). The
size of this locus was 4.1 years (1.01 SD), and it ex-
plained ∼13% of the genetic variance in age at onset in
the current sample, after APOE was accounted for. We
did not attempt to extract models for smaller QTLs.
Discussion
By use of novel Bayesian MCMC joint linkage and ol-
igogenic segregation analysis, we have presented here
strong evidence for a new LOFAD locus on chromosome
19p that affects AD age at onset. We also showed that
these methods provide support for linkage of LOFAD
to APOE, when APOE is also included as a marker;
this evidence for linkage probably would have been
missed in an ordinary genome scan, which would not
have included APOE as a marker. The large increase in
linkage signal on 19p resulting from the use of a method
of analysis that allows for efﬁcient adjustment for a
known genetic covariate demonstrates the importance
of incorporating such information into the geneticmodel
in the search for further LOFAD loci. We have also pre-
sented modest corroboratory evidence for a locus on
chromosome 10 to a location that coincides with one
reported elsewhere. There is no evidence for linkage of
age at onset of LOFAD in our data set to locations pre-
viously reported as harboring AD risk loci on chro-
mosomes 9, 12, or 21. In addition, the analysis of A2M
and LRP as candidate genes on chromosome 12 does
not support genotype-speciﬁc age-at-onset effects.
Three lines of evidence indicate that the 19p signal
is not APOE. First, the location of the peak signal is
almost 40 cM away from that of APOE. Some varia-
bility in location among studies is expected, but this
distance between the 19p signal and APOE is too great
to be consistent with a single gene at APOE. Second,
the analysis of chromosome 19 identiﬁed evidence for
two signals on chromosome 19. One of these signals is
due to APOE (1) because of its location, (2) because
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the signal on 19q increases when APOE is added as a
marker, and it localizes more accurately to the APOE
location, and (3) because the signal disappears when
APOE genotypes are used as covariates in the linkage
analysis. In contrast to this, the third line of evidence
is that the 19p signal is insensitive to the use of APOE
as a marker and increases, rather than decreases, in
strength when APOE is used as a covariate. This is
inconsistent with this signal representing an artifact of
the APOE locus and supports the conclusion that the
19p locus is distinct from APOE. The localization of
the 19q signal near APOE when APOE was included
as a marker was much better, suggesting that the initial
localization of APOE may have been imprecise. The
imprecision might be a result of the assumption in this
analysis of a diallelic trait-locus model, whereas APOE
is a three-allele system with each allele contributing dif-
ferently to age at onset. Other linkage analyses of the
APOE region in different data sets obtain similarly dis-
placed locations for the position of the strongest linkage
evidence near APOE (Myers et al. 2002), possibly for
the same reason.
On the basis of the size of the QTL and the similarity
of the trait model to that estimated elsewhere, the QTL
responsible for the linkage signal on 19p is compatible
with being the largest QTL suggested by a previous
oligogenic segregation analysis (Daw et al. 2000b). The
use of these MCMC methods to predict the number of
QTLs segregating in a set of families has not yet been
extensively tested. However, preliminary results based
on simulated (Wijsman and Yu, in press) and real data
analyses (Gagnon et al. 2003; F. Gagnon, personal com-
munication) suggest that oligogenic segregation analy-
ses in the absence of marker data produce results that
are consistent either with the simulated truth or with
the number of linkage signals found in subsequent ge-
nome scans of real data. If this holds up for these fam-
ilies with LOFAD, we can expect to be able to ﬁnd one
or two more QTLs of reasonable size in this data set,
on the basis of the size of the 19pQTL and the estimated
sizes of additional QTLs from the current and a previous
oligogenic segregation analysis of these data (Daw et
al. 2000b).
An early linkage analysis of chromosome 19 also gave
modest support for the existence of a LOFAD gene to
approximately the same location as that reported here
(Pericak-Vance et al. 1991). This observation was not
pursued when evidence that APOE was involved in LO-
FAD surfaced in the same sample. However, our results
suggest that reanalysis of these data with methods such
as those used here could be useful, since the oligogenic
model may be more appropriate for detecting evidence
for linkage in the presence of common variation than
were the analysis methods previously used.
Certain assumptions are implicit or explicit in the
MCMC analysis method used here, but most are un-
likely to have major effects on the conclusions pertain-
ing to gene linkage. Violation of the within-genotype
normality assumption is unlikely to result in a false
linkage signal, although it may result in overestimation
of the total number of contributing QTLs (but not the
number of larger QTLs) (Wijsman and Yu, in press).
Similarly, any residual family effect is also likely to man-
ifest only as additional QTLs with small contribution
to the variance in the model. This would include small
biases in estimated age at onset introduced by awareness
of AD in family members. One assumption is that all
individuals will eventually develop AD; however, the
late onset of this disease means that it is only important
that the model approximates the lower tail of the onset
distribution for unaffected individuals. Again, this is
unlikely to be critical in affecting the linkage signal. The
additivity assumption across contributing loci may af-
fect estimates of QTL model parameters but is unlikely
to cause a false-positive linkage signal. Finally, the as-
sumption of diallelic QTLs may affect the accuracy of
gene localization, as appears to be occurring for APOE.
Relaxation of these assumptions is not currently a re-
alistic option, although it may be possible in the future,
with further development of the MCMC methods used
here.
Although we obtained only weak evidence of linkage
to one previously reported region on chromosome 10
among the four other chromosomes that we investi-
gated, there are numerous explanations for discrepan-
cies in mapping results among studies. In addition to
the standard explanations involving statistical error and
sample sizes, there are differences in ascertainment cri-
teria. The NIMH AD data set, on which a number of
published reports of linkage are based, consists of a
large number of small families. In contrast, our data set
includes a number of very large pedigrees. Differences
in the ascertainment criteria involving pedigree sizes and
structures can change the proportion of the sample car-
rying particular risk alleles for a complex trait (Mc-
Carthy et al. 1998; Goddard 1999), which can, in turn,
affect the power to detect linkage in different studies.
Thus, it is possible that some differences are a function
of the different pedigree ascertainment. Another differ-
ence among studies is the phenotype of the analysis.
Here we have performed analysis on age at onset of AD
with adjustment of age at onset for theAPOE genotype;
in other studies, the phenotype has been AD, possibly
stratiﬁed on some measure of APOE genotypes in the
family members. The two phenotypes are clearly re-
lated, but the underlying genetic basis need not be
identical.
There are a number of known genes in the vicinity
of the linkage signal on chromosome 19p. Most do not
have any obvious connection with AD. The low-density
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lipoprotein receptor (LDLR [MIM 606945]) is 2–3 cM
away from the location of the peak IR on 19p13.3 and
falls below the 90th percentile in the posterior distri-
bution of QTL locations on this chromosome. This is
suggestive because of the APOE effect on AD and be-
cause of the role of APOE in cardiovascular biology.
PIN1 (peptidyl-prolyl cis/trans isomerase, NIMA-inter-
acting, 1 [MIM 601052]) is also nearby. It has been
suggested that PIN1 can restore phosphorylated tau and
can prevent helical ﬁlament formation in AD (Lu et al.
1999). Finally, ELAV1 and ELAV3 (embryonic lethal,
abnormal vision, Drosophila, homolog-like 1 [MIM
603466] and 3 [MIM 603458]) are close to LDLR. The
ELAV family appears to act in neurons, and human
homologues have been implicated in a variety of post-
transcriptional processes (Perrone-Bizzozero and Bol-
ognani 2002; Loria et al. 2003). Future identiﬁcation
of the 19p gene will aid in understanding factors inﬂu-
encing age at onset of AD.
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